Country Club Bank Grows Position in Kenvue Inc. $KVUE

Country Club Bank increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 22.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 303,211 shares of the company’s stock after acquiring an additional 56,085 shares during the quarter. Country Club Bank’s holdings in Kenvue were worth $4,954,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of KVUE. HF Advisory Group LLC boosted its holdings in shares of Kenvue by 16.6% during the 3rd quarter. HF Advisory Group LLC now owns 155,943 shares of the company’s stock valued at $2,531,000 after purchasing an additional 22,148 shares during the last quarter. Nilsine Partners LLC purchased a new stake in shares of Kenvue in the third quarter worth about $163,000. Jacobs & Co. CA boosted its stake in Kenvue by 31.4% during the third quarter. Jacobs & Co. CA now owns 253,617 shares of the company’s stock valued at $4,116,000 after buying an additional 60,585 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Kenvue by 1.2% during the second quarter. Corient Private Wealth LLC now owns 413,221 shares of the company’s stock valued at $8,649,000 after buying an additional 4,785 shares during the last quarter. Finally, Valeo Financial Advisors LLC grew its holdings in Kenvue by 11.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 16,429 shares of the company’s stock valued at $344,000 after buying an additional 1,688 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Activity

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The stock was acquired at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.68% of the stock is owned by company insiders.

Kenvue Stock Up 0.3%

NYSE KVUE opened at $17.30 on Thursday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The firm has a market capitalization of $33.13 billion, a price-to-earnings ratio of 23.06 and a beta of 0.60. The company has a fifty day moving average of $16.28 and a two-hundred day moving average of $18.95.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KVUE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Bank of America decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.